Sorafenib tosylate for advanced kidney cancer: lucky loser and magic box at the same time

Despite being the very first molecular targeted agents registered for the treatment of advanced kidney cancer (in the post-cytokines setting), Sorafenib seemed to lose its momentum as a credible first-line treatment option, when it proved not to be superior to Interferon within a randomized phase II...

Полное описание

Сохранить в:
Библиографические подробности
Главный автор: Camillo Porta (Автор)
Формат:
Опубликовано: Frontiers Media S.A., 2011-09-01T00:00:00Z.
Предметы:
Online-ссылка:Connect to this object online.
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Internet

Connect to this object online.

3rd Floor Main Library

Подробно о фондах из 3rd Floor Main Library
Шифр: A1234.567
Копировать 1 Доступно